

### Supplementary Figure S3

Inhibitor	Doubling time (days) and 95% CI			
	MDA-MB-175-VII	LUAD-0061AS3	HBECp53-CD74-NRG1	HCC-95
Control	2.96 (2.91 to 3.02)	3.01 (2.78 to 3.30)	1.71 (1.67 to 1.75)	1.05 (1.03 to 1.06)
Seribantumab-0.1 $\mu$ M	4.84 (4.65 to 5.05)	4.58 (3.94 to 5.67)	2.11 (2.04 to 2.20)	1.81 (1.75 to 1.88)
Seribantumab-1 $\mu$ M	8.50 (7.86 to 9.31)	5.76 (4.30 to 10.27)	2.43 (2.23 to 2.72)	1.50 (1.48 to 1.52)
Seribantumab-10 $\mu$ M	42.03 (25.32 to 161.9)	7.91 (5.76 to 14.57)	4.12 (3.07 to 8.44)	1.50 (1.41 to 1.66)
Afatinib-0.05 $\mu$ M	-1.74 (-2.35 to -1.22)	-15.90 (-Inf to -6.03)	7.02 (5.84 to 9.11)	ND

**Supplementary Figure S3. Doubling time of cells treated with afatinib or seribantumab.** Cells were treated with vehicle (control), or seribantumab and afatinib at the indicated concentrations and then counted every 24-48 h. The growth curves are shown in **Figure 2 C-F**. The doubling time and 95% confidence interval were determined by non-linear regression of data fitted to an exponential growth model using Graphpad Prism 8.